References

Albert DV et al. Unique Characteristics of the photoparoxysmal response in patients with neuronal ceroid lipofuscinosis type 2: can EEG be a biomarker? J Child Neurol. 2016;31:1475-1482. doi: 10.1177/0883073816658659.

Barcenas M et al. Tandem mass spectrometry assays of palmitoyl protein thioesterase 1 and tripeptidyl peptidase activity in dried blood spots for the detection of neuronal ceroid lipofuscinoses in newborns. Anal Chem 2014;86:7962–7968

Chang M et al. CLN2. In: Mole S, Williams R, and Goebel HH, eds. The neuronal ceroid lipofuscinoses (Batten Disease). 2nd ed. Oxford, United Kingdom: Oxford University Press; 2011:80-109. dx.doi.org/10.1093/med/9780199590018.003.0007.

Claussen M et al. Incidence of neuronal ceroid-lipofuscinoses in West Germany: variation of a method for studying autosomal recessive disorders. Am J Med Genet. 1992;42:536-538.

Fietz M et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119:160-167 doi: 10.1016/j.ymgme.2016.07.011.

Fietz M, et al. Expert recommendations for the laboratory diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): diagnostic algorithm and best practice guidelines for a timely diagnosis. Poster session presented at: The 12th Annual WORLD Symposium; February – March 2016; San Diego, CA.

Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 2003; 62(1):1-13. doi: http://dx.doi.org/10.1093/jnen/62.1.1.

Haltia M. The neuronal ceroid-lipofuscinoses: from past to present. Biochimica et Biophysica Acta. 2006;1762:850-856. http://linkinghub.elsevier.com/retrieve/pii/S0925-4439(12)00198-6

Johannsen J et al. Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease. Neuropediatrics. 2016 Jun;47(3):194-196. doi: 10.1055/s-0036-1579784.

Kousi M et al. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33:42-63. doi: 10.1002/humu.21624.

Mole SE et al. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6:107-126. doi:10.1007/s10048-005-0218-3.

Mole SE and Williams RE. Neuronal ceroid-lipofuscinoses. 2001 Oct 10 [Updated 2013 Aug 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [internet]. Seattle, WA: University of Washington; 1993-2016. http://www.ncbi.nlm.nih.gov/books/NBK1428/

Nickel M et al. Natural history of CLN2 disease: quantitative assessment of disease characteristics and rate of progression. Poster session presented at: The 12th Annual WORLD Symposium; February - March 2016; San Diego, CA.

Orlin A et al. Spectrum of ocular manifestations in CLN2-associated Batten (Jansky-Bielschowsky) Disease correlate with advancing age and deteriorating neurological function. PLoS One. 2013;8:e73128. doi:10.1371/journal.pone.0073128.

Pérez-Poyato MS et al. Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013;28:470-478. doi: 10.1177/0883073812448459

Schulz A et al. Neuronal ceroid lipofuscinosis-2 (CLN2) disorder, a type of Batten disease caused by TPP1 enzyme deficiency: current knowledge of the natural history from international experts. Poster session presented at: The Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium; September 2015; Lyon, France.

Schulz A et al. NCL diseases - clinical perspectives. Biochimica et Biophysica Acta. 2013;1832:1801-1806. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631127/

Steinfeld R et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112:347-354.

Williams RE et al. Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochimica et Biophysica Acta. 2006;1762:865-872. http://www.sciencedirect.com/science/article/pii/S0925443906001281

Williams RE et al. Expert opinion on the management of CLN2 disease. Poster session presented at: The 12th Annual WORLD Symposium; February – March 2016; San Diego, CA.

Williams RE and Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79:183-191. doi: 10.1212/WNL.0b013e31825f0547.

Worgall S et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-­associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19:463-474. doi: 10.1089/hum.2008.022.